Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Recurrent Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme Treatment Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 AU-105
    • 1.4.3 Axitinib
    • 1.4.4 AXL-1717
    • 1.4.5 AZD-7451
    • 1.4.6 Others
  • 1.5 Market by Application
    • 1.5.1 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): Recurrent Glioblastoma Multiforme Treatment Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Recurrent Glioblastoma Multiforme Treatment Industry
      • 1.6.1.1 Recurrent Glioblastoma Multiforme Treatment Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Recurrent Glioblastoma Multiforme Treatment Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Recurrent Glioblastoma Multiforme Treatment Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Recurrent Glioblastoma Multiforme Treatment Market Perspective (2015-2026)
  • 2.2 Recurrent Glioblastoma Multiforme Treatment Growth Trends by Regions
    • 2.2.1 Recurrent Glioblastoma Multiforme Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Recurrent Glioblastoma Multiforme Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Recurrent Glioblastoma Multiforme Treatment Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Recurrent Glioblastoma Multiforme Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Market Size
    • 3.1.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio
    • 3.2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme Treatment Revenue in 2019
  • 3.3 Recurrent Glioblastoma Multiforme Treatment Key Players Head office and Area Served
  • 3.4 Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service
  • 3.5 Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2021-2026)

5 Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)
  • 5.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 6.2 Recurrent Glioblastoma Multiforme Treatment Key Players in North America (2019-2020)
  • 6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 6.4 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 7.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Europe (2019-2020)
  • 7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 7.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

8 China

  • 8.1 China Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 8.2 Recurrent Glioblastoma Multiforme Treatment Key Players in China (2019-2020)
  • 8.3 China Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 8.4 China Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 9.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Japan (2019-2020)
  • 9.3 Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 9.4 Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 10.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

11 India

  • 11.1 India Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 11.2 Recurrent Glioblastoma Multiforme Treatment Key Players in India (2019-2020)
  • 11.3 India Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 11.4 India Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 12.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 12.4 Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Boehringer Ingelheim GmbH
    • 13.1.1 Boehringer Ingelheim GmbH Company Details
    • 13.1.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue
    • 13.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.1.4 Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020))
    • 13.1.5 Boehringer Ingelheim GmbH Recent Development
  • 13.2 Boston Biomedical, Inc.
    • 13.2.1 Boston Biomedical, Inc. Company Details
    • 13.2.2 Boston Biomedical, Inc. Business Overview and Its Total Revenue
    • 13.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.2.4 Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.2.5 Boston Biomedical, Inc. Recent Development
  • 13.3 Bristol-Myers Squibb Company
    • 13.3.1 Bristol-Myers Squibb Company Company Details
    • 13.3.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
    • 13.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.3.4 Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.3.5 Bristol-Myers Squibb Company Recent Development
  • 13.4 Cantex Pharmaceuticals, Inc.
    • 13.4.1 Cantex Pharmaceuticals, Inc. Company Details
    • 13.4.2 Cantex Pharmaceuticals, Inc. Business Overview and Its Total Revenue
    • 13.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.4.4 Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.4.5 Cantex Pharmaceuticals, Inc. Recent Development
  • 13.5 Cavion LLC
    • 13.5.1 Cavion LLC Company Details
    • 13.5.2 Cavion LLC Business Overview and Its Total Revenue
    • 13.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.5.4 Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.5.5 Cavion LLC Recent Development
  • 13.6 Celldex Therapeutics, Inc.
    • 13.6.1 Celldex Therapeutics, Inc. Company Details
    • 13.6.2 Celldex Therapeutics, Inc. Business Overview and Its Total Revenue
    • 13.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.6.4 Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.6.5 Celldex Therapeutics, Inc. Recent Development
  • 13.7 Coherus BioSciences, Inc.
    • 13.7.1 Coherus BioSciences, Inc. Company Details
    • 13.7.2 Coherus BioSciences, Inc. Business Overview and Its Total Revenue
    • 13.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.7.4 Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.7.5 Coherus BioSciences, Inc. Recent Development
  • 13.8 Cortice Biosciences, Inc.
    • 13.8.1 Cortice Biosciences, Inc. Company Details
    • 13.8.2 Cortice Biosciences, Inc. Business Overview and Its Total Revenue
    • 13.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.8.4 Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.8.5 Cortice Biosciences, Inc. Recent Development
  • 13.9 Eisai
    • 13.9.1 Eisai Company Details
    • 13.9.2 Eisai Business Overview and Its Total Revenue
    • 13.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.9.4 Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.9.5 Eisai Recent Development
  • 13.10 Eli Lilly and Company
    • 13.10.1 Eli Lilly and Company Company Details
    • 13.10.2 Eli Lilly and Company Business Overview and Its Total Revenue
    • 13.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Introduction
    • 13.10.4 Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.10.5 Eli Lilly and Company Recent Development
  • 13.11 EnGeneIC Ltd
    • 10.11.1 EnGeneIC Ltd Company Details
    • 10.11.2 EnGeneIC Ltd Business Overview and Its Total Revenue
    • 10.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Introduction
    • 10.11.4 EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 10.11.5 EnGeneIC Ltd Recent Development
  • 13.12 ERC Belgium SA
    • 10.12.1 ERC Belgium SA Company Details
    • 10.12.2 ERC Belgium SA Business Overview and Its Total Revenue
    • 10.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Introduction
    • 10.12.4 ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 10.12.5 ERC Belgium SA Recent Development
  • 13.13 GenSpera, Inc.
    • 10.13.1 GenSpera, Inc. Company Details
    • 10.13.2 GenSpera, Inc. Business Overview and Its Total Revenue
    • 10.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
    • 10.13.4 GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 10.13.5 GenSpera, Inc. Recent Development
  • 13.14 Genzyme Corporation
    • 10.14.1 Genzyme Corporation Company Details
    • 10.14.2 Genzyme Corporation Business Overview and Its Total Revenue
    • 10.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Introduction
    • 10.14.4 Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 10.14.5 Genzyme Corporation Recent Development
  • 13.15 GW Pharmaceuticals Plc
    • 10.15.1 GW Pharmaceuticals Plc Company Details
    • 10.15.2 GW Pharmaceuticals Plc Business Overview and Its Total Revenue
    • 10.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Introduction
    • 10.15.4 GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 10.15.5 GW Pharmaceuticals Plc Recent Development
  • 13.16 ImmunoCellular Therapeutics, Ltd.
    • 10.16.1 ImmunoCellular Therapeutics, Ltd. Company Details
    • 10.16.2 ImmunoCellular Therapeutics, Ltd. Business Overview and Its Total Revenue
    • 10.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Introduction
    • 10.16.4 ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
    • 10.16.5 ImmunoCellular Therapeutics, Ltd. Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Recurrent Glioblastoma Multiforme Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Recurrent Glioblastoma Multiforme Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Boehringer Ingelheim GmbH
    Boston Biomedical, Inc.
    Bristol-Myers Squibb Company
    Cantex Pharmaceuticals, Inc.
    Cavion LLC
    Celldex Therapeutics, Inc.
    Coherus BioSciences, Inc.
    Cortice Biosciences, Inc.
    Eisai
    Eli Lilly and Company
    EnGeneIC Ltd
    ERC Belgium SA
    GenSpera, Inc.
    Genzyme Corporation
    GW Pharmaceuticals Plc
    ImmunoCellular Therapeutics, Ltd.

    Market segment by Type, the product can be split into
    AU-105
    Axitinib
    AXL-1717
    AZD-7451
    Others
    Market segment by Application, split into
    Hospital
    Clinic
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Recurrent Glioblastoma Multiforme Treatment status, future forecast, growth opportunity, key market and key players.
    To present the Recurrent Glioblastoma Multiforme Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Recurrent Glioblastoma Multiforme Treatment are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now